Clinical Trial Update: Proof Of Mechanism Study To Determine Efficacy Of PF-04455242 In Blocking Spiradoline (PF-00345768) Stimulated Prolactin Release [Phase 1]

View source ↗

Summary

Pfizer completed a Phase 1 proof-of-mechanism study to determine if PF-04455242 can block spiradoline-stimulated prolactin release in bipolar depression.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Drugs mentioned

• PF-04455242 (PF-04455242)
• Spiradoline (PF-00345768)

Snippet

Sponsor: Pfizer | Conditions: Bipolar Depression | Phase 1 | Status: COMPLETED